June 10, 2024
1,133
9
0.79%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
47:28Now PlayingThe rise of GLP-1 drugs, like Ozempic, is a potentially existential threat to the makers of salty, sugary, high-calorie snack foods. But it's obvious that the gigantic food industry will search out ways to adapt. So what types of new products will they sell? How will they be flavored? How will they be packaged and marketed? On this episode of the podcast, we speak with Barb Stuckey. She is the chief innovation and marketing officer at Mattson, a San Francisco Bay Area company that helps food producers find the next big flavor. Her team recently undertook a big study of Ozempic users to get a better understanding of how it changed their diets. She speaks to us about what they learned, what new types of products are in development, and how food manufacturers find the next big thing.
Bloomberg's Joe Weisenthal and Tracy Alloway analyze the weird patterns, the complex issues and the newest market crazes. Join the conversation every Monday and Thursday for interviews with the most interesting minds in finance, economics and markets.
Subscribe to Bloomberg Podcasts
Check out more Odd Lots
Get the Odd Lots newsletter via
And for all things Odd Lots, visit
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
#Bloomberg #Podcast #OddLots
Follow Bloomberg Podcasts on Twitter
For coverage on news, markets and more
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.